Usefulness of 18 F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels

We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year wer...

Full description

Saved in:
Bibliographic Details
Published in:Molecular imaging and radionuclide therapy 2018-06, Vol.27 (2), p.66
Main Authors: Vural Topuz, Özge, Görtan, Fatma Arzu, Kaya Döner, Zübeyde Rana, Önsel, Çetin, Sayman, Haluk Burçak
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 2
container_start_page 66
container_title Molecular imaging and radionuclide therapy
container_volume 27
creator Vural Topuz, Özge
Görtan, Fatma Arzu
Kaya Döner, Zübeyde Rana
Önsel, Çetin
Sayman, Haluk Burçak
description We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p
doi_str_mv 10.4274/mirt.70783
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_29889028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>29889028</sourcerecordid><originalsourceid>FETCH-pubmed_primary_298890283</originalsourceid><addsrcrecordid>eNqFjrFuwjAURT1QFURZ-gHo_UDANhYxc0rKABVS0xm5ygu4tZ0oz6bi75uhzL3L0T26w2XsWfCFkrlaetvHRc5zvRqxiRRqnQkl1JjNiL74EC3XXOtHNpYbrTdc6glLH4RNcgGJoG1AaCiz8uUVjttqWVRgAxQpmoBtIjigM6H1Bo4mWgyR4MfGC7zheehXhPfB2YAO9jffDb6tkcCEGnb2fIHCmf4b9nhFR0_soTGOcPbHKZuX26rYZV369Fifut56099O95-rfwe_31BMvA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Usefulness of 18 F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><creator>Vural Topuz, Özge ; Görtan, Fatma Arzu ; Kaya Döner, Zübeyde Rana ; Önsel, Çetin ; Sayman, Haluk Burçak</creator><creatorcontrib>Vural Topuz, Özge ; Görtan, Fatma Arzu ; Kaya Döner, Zübeyde Rana ; Önsel, Çetin ; Sayman, Haluk Burçak</creatorcontrib><description>We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p&lt;0.001) than that in patients with positive SLNBs. Our results showed that F-FDG PET/CT will most likely (86.4%) be negative during the first postoperative year in patients with a negative SLNB. Therefore, it is concluded that this modality would not provide any significant clinical contribution within this time frame.</description><identifier>ISSN: 2146-1414</identifier><identifier>DOI: 10.4274/mirt.70783</identifier><identifier>PMID: 29889028</identifier><language>eng</language><publisher>Turkey</publisher><ispartof>Molecular imaging and radionuclide therapy, 2018-06, Vol.27 (2), p.66</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29889028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vural Topuz, Özge</creatorcontrib><creatorcontrib>Görtan, Fatma Arzu</creatorcontrib><creatorcontrib>Kaya Döner, Zübeyde Rana</creatorcontrib><creatorcontrib>Önsel, Çetin</creatorcontrib><creatorcontrib>Sayman, Haluk Burçak</creatorcontrib><title>Usefulness of 18 F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels</title><title>Molecular imaging and radionuclide therapy</title><addtitle>Mol Imaging Radionucl Ther</addtitle><description>We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p&lt;0.001) than that in patients with positive SLNBs. Our results showed that F-FDG PET/CT will most likely (86.4%) be negative during the first postoperative year in patients with a negative SLNB. Therefore, it is concluded that this modality would not provide any significant clinical contribution within this time frame.</description><issn>2146-1414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFjrFuwjAURT1QFURZ-gHo_UDANhYxc0rKABVS0xm5ygu4tZ0oz6bi75uhzL3L0T26w2XsWfCFkrlaetvHRc5zvRqxiRRqnQkl1JjNiL74EC3XXOtHNpYbrTdc6glLH4RNcgGJoG1AaCiz8uUVjttqWVRgAxQpmoBtIjigM6H1Bo4mWgyR4MfGC7zheehXhPfB2YAO9jffDb6tkcCEGnb2fIHCmf4b9nhFR0_soTGOcPbHKZuX26rYZV369Fifut56099O95-rfwe_31BMvA</recordid><startdate>20180607</startdate><enddate>20180607</enddate><creator>Vural Topuz, Özge</creator><creator>Görtan, Fatma Arzu</creator><creator>Kaya Döner, Zübeyde Rana</creator><creator>Önsel, Çetin</creator><creator>Sayman, Haluk Burçak</creator><scope>NPM</scope></search><sort><creationdate>20180607</creationdate><title>Usefulness of 18 F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels</title><author>Vural Topuz, Özge ; Görtan, Fatma Arzu ; Kaya Döner, Zübeyde Rana ; Önsel, Çetin ; Sayman, Haluk Burçak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_298890283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vural Topuz, Özge</creatorcontrib><creatorcontrib>Görtan, Fatma Arzu</creatorcontrib><creatorcontrib>Kaya Döner, Zübeyde Rana</creatorcontrib><creatorcontrib>Önsel, Çetin</creatorcontrib><creatorcontrib>Sayman, Haluk Burçak</creatorcontrib><collection>PubMed</collection><jtitle>Molecular imaging and radionuclide therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vural Topuz, Özge</au><au>Görtan, Fatma Arzu</au><au>Kaya Döner, Zübeyde Rana</au><au>Önsel, Çetin</au><au>Sayman, Haluk Burçak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Usefulness of 18 F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels</atitle><jtitle>Molecular imaging and radionuclide therapy</jtitle><addtitle>Mol Imaging Radionucl Ther</addtitle><date>2018-06-07</date><risdate>2018</risdate><volume>27</volume><issue>2</issue><spage>66</spage><pages>66-</pages><issn>2146-1414</issn><abstract>We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p&lt;0.001) than that in patients with positive SLNBs. Our results showed that F-FDG PET/CT will most likely (86.4%) be negative during the first postoperative year in patients with a negative SLNB. Therefore, it is concluded that this modality would not provide any significant clinical contribution within this time frame.</abstract><cop>Turkey</cop><pmid>29889028</pmid><doi>10.4274/mirt.70783</doi></addata></record>
fulltext fulltext
identifier ISSN: 2146-1414
ispartof Molecular imaging and radionuclide therapy, 2018-06, Vol.27 (2), p.66
issn 2146-1414
language eng
recordid cdi_pubmed_primary_29889028
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central
title Usefulness of 18 F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T10%3A29%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Usefulness%20of%2018%20F-FDG%20PET/CT%20in%20Cutaneous%20Melanoma%20Patients%20with%20Negative%20Sentinel%20Lymph%20Nodes%20and%20High%20Clark%20Levels&rft.jtitle=Molecular%20imaging%20and%20radionuclide%20therapy&rft.au=Vural%20Topuz,%20%C3%96zge&rft.date=2018-06-07&rft.volume=27&rft.issue=2&rft.spage=66&rft.pages=66-&rft.issn=2146-1414&rft_id=info:doi/10.4274/mirt.70783&rft_dat=%3Cpubmed%3E29889028%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_298890283%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/29889028&rfr_iscdi=true